126 related articles for article (PubMed ID: 33152695)
1. Prostate Cancer Grade and Stage Misclassification in Active Surveillance Candidates: Black Versus White Patients.
Stolzenbach LF; Rosiello G; Pecoraro A; Palumbo C; Luzzago S; Deuker M; Tian Z; Knipper AS; Pompe R; Zorn KC; Shariat SF; Chun FKH; Graefen M; Saad F; Karakiewicz PI
J Natl Compr Canc Netw; 2020 Nov; 18(11):1492-1499. PubMed ID: 33152695
[TBL] [Abstract][Full Text] [Related]
2. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.
Yang DD; Mahal BA; Muralidhar V; Nezolosky MD; Vastola ME; Labe SA; Boldbaatar N; King MT; Martin NE; Orio PF; Beard CJ; Hoffman KE; Trinh QD; Spratt DE; Feng FY; Nguyen PL
Eur Urol Focus; 2019 Jan; 5(1):69-76. PubMed ID: 28753811
[TBL] [Abstract][Full Text] [Related]
3. Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance.
Yang DD; Mahal BA; Muralidhar V; Vastola ME; Boldbaatar N; Labe SA; Nezolosky MD; Orio PF; King MT; Martin NE; Mouw KW; Trinh QD; Nguyen PL
Clin Genitourin Cancer; 2018 Jun; 16(3):226-234. PubMed ID: 29196209
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Mexican-American vs Caucasian prostate cancer active surveillance candidates.
Collà Ruvolo C; Stolzenbach LF; Nocera L; Deuker M; Mistretta FA; Luzzago S; Tian Z; Longo N; Graefen M; Chun FKH; Saad F; Briganti A; De Cobelli O; Mirone V; Karakiewicz PI
Urol Oncol; 2021 Jan; 39(1):74.e1-74.e7. PubMed ID: 32950397
[TBL] [Abstract][Full Text] [Related]
5. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
[TBL] [Abstract][Full Text] [Related]
6. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
Butler SS; Mahal BA; Lamba N; Mossanen M; Martin NE; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2019 Sep; 125(18):3164-3171. PubMed ID: 31150125
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity in D'Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility.
Schiffmann J; Wenzel P; Salomon G; Budäus L; Schlomm T; Minner S; Wittmer C; Kraft S; Krech T; Steurer S; Sauter G; Beyer B; Boehm K; Tilki D; Michl U; Huland H; Graefen M; Karakiewicz PI
Urol Oncol; 2015 Jul; 33(7):329.e13-9. PubMed ID: 25960411
[TBL] [Abstract][Full Text] [Related]
8. Subtyping the Risk of Intermediate Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy.
Patel HD; Gupta M; Tosoian JJ; Carter HB; Partin AW; Epstein JI
J Urol; 2018 Nov; 200(5):1068-1074. PubMed ID: 29673946
[TBL] [Abstract][Full Text] [Related]
9. Effects of pathological upstaging or upgrading on metastasis and cancer-specific mortality in men with clinical low-risk prostate cancer.
Kovac E; Vertosick EA; Sjoberg DD; Vickers AJ; Stephenson AJ
BJU Int; 2018 Dec; 122(6):1003-1009. PubMed ID: 29802773
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
[TBL] [Abstract][Full Text] [Related]
11. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
12. Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates.
Sorce G; Flammia RS; Hoeh B; Chierigo F; Hohenhorst L; Panunzio A; Stabile A; Gandaglia G; Tian Z; Tilki D; Terrone C; Gallucci M; Chun FKH; Antonelli A; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
Prostate; 2022 Jun; 82(10):1040-1050. PubMed ID: 35365851
[TBL] [Abstract][Full Text] [Related]
13. Role of Chronic Inflammation as a Predictor of Upstaging/Upgrading in Prostate Cancer: Finding a New Group Eligible for Active Surveillance.
Nowroozi MR; Ayati M; Amini E; Aghamiri SM; Momeni SA; Ohadian Moghadam S; Valizadeh F
Urol J; 2020 Jun; 17(4):370-373. PubMed ID: 31953833
[TBL] [Abstract][Full Text] [Related]
14. Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance.
Ferro M; Lucarelli G; Bruzzese D; Di Lorenzo G; Perdonà S; Autorino R; Cantiello F; La Rocca R; Busetto GM; Cimmino A; Buonerba C; Battaglia M; Damiano R; De Cobelli O; Mirone V; Terracciano D
Oncotarget; 2017 Mar; 8(11):18424-18434. PubMed ID: 27793023
[TBL] [Abstract][Full Text] [Related]
15. The presence of high-grade prostatic intraepithelial neoplasia or atypia on prostate biopsy does not adversely affect prostatectomy outcomes for patients otherwise eligible for active surveillance.
Pietzak EJ; Kabarriti AE; Mucksavage P; Bavaria T; Van Arsdalen K; Malkowicz SB; Wein AJ; Guzzo TJ
Urology; 2014 Dec; 84(6):1442-7. PubMed ID: 25288572
[TBL] [Abstract][Full Text] [Related]
16. Defining Prostate Cancer at Favorable Intermediate Risk: The Potential Utility of Magnetic Resonance Imaging and Genomic Tests.
Falagario UG; Beksac AT; Martini A; Cumarasamy S; Gupta A; Prasad S; Thulasidass H; Shah QN; Jayaratna I; Lewis S; Rastinehad AR; Taouli B; Cormio L; Carrieri G; Tewari AK
J Urol; 2019 Jul; 202(1):102-107. PubMed ID: 30730408
[TBL] [Abstract][Full Text] [Related]
17. Histologic upgrading in patients eligible for active surveillance on saturation biopsy.
Chung PH; Darwish OM; Roehrborn CG; Kapur P; Lotan Y
Can J Urol; 2015 Feb; 22(1):7656-60. PubMed ID: 25694015
[TBL] [Abstract][Full Text] [Related]
18. The pathological upgrading after radical prostatectomy in low-risk prostate cancer patients who are eligible for active surveillance: How safe is it to depend on bioptic pathology?
Verep S; Erdem S; Ozluk Y; Kilicaslan I; Sanli O; Ozcan F
Prostate; 2019 Sep; 79(13):1523-1529. PubMed ID: 31269285
[TBL] [Abstract][Full Text] [Related]
19. Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance.
Busch J; Magheli A; Leva N; Ferrari M; Kramer J; Klopf C; Kempkensteffen C; Miller K; Brooks JD; Gonzalgo ML
BJU Int; 2014 Oct; 114(4):517-21. PubMed ID: 24112652
[TBL] [Abstract][Full Text] [Related]
20. How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator.
Gandaglia G; van den Bergh RCN; Tilki D; Fossati N; Ost P; Surcel CI; Sooriakumaran P; Tsaur I; Valerio M; Kretschmer A; Zaffuto E; Salomon L; Montorsi F; Graefen M; van der Poel H; de la Taille A; Briganti A; Ploussard G;
BJU Int; 2018 Nov; 122(5):823-830. PubMed ID: 29772103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]